• NuWays reiterated a BUY rating on Eckert & Ziegler, setting a 12-month target price of EUR 21.50.
• Report flags a valuation gap versus recent radiopharma M&A, citing implied multiples of 5.3x sales and 16x manufacturing EBITDA for ITM.
• NuWays argues consolidation increases demand for independent isotope supply, positioning the company as a non-competing partner for drug developers.
• Note highlights manufacturing reliability as a key differentiator, citing recent FDA setbacks tied to external manufacturing issues at peers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eckert & Ziegler SE published the original content used to generate this news brief via EQS News (Ref. ID: rc_27066) on October 13, 2026, and is solely responsible for the information contained therein.